Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
248
resultados
Última actualización
18/08/2026 [06:52:00]
Resultados 75 a 100 de 248
Resumen de: US20260232601A1
Disclosed herein are functionalized polyethylenimine compounds for use as nanoparticles. Methods of making the compounds and nanoparticles comprising a cargo and methods of delivering a nanoparticle comprising a cargo are provided. The nanoparticles of the present invention can be utilized in methods of delivering cargo in a tissue specific manner, providing low toxicity and efficient release of cargo in the cell.
Resumen de: US20260234204A1
The invention relates to truncated isolated BRK peptides and functional peptides thereof that inhibit the phosphorylation of p27Kip1 and the resulting kinase activity of CDK2 and CDK4; and to pharmaceutical compositions thereof. The invention further relates to the use of the isolated peptides in methods of treating cancer in subject in need thereof. The methods of treating cancer include methods of treating pancreatic cancer.
Resumen de: US20260232777A1
The present invention relates to a pharmaceutical combination comprising (i) at least one nucleic acid comprising an antisense and flipped sequence of a fragment of a sequence coding for a kanamycin resistance protein and (ii) at least one non-immunosuppressive inducer of tumor cell apoptosis, wherein said nucleic acid is formulated with a nano-vehicle. Said nucleic acid is preferably pVAX14 plasmid, said non-immunosuppressive inducer of tumor cell apoptosis is preferably ATRA, an arsenic-related compound or azacytidine. The present invention also relates to the pharmaceutical combination as defined above for use in the treatment of cancer or infectious diseases, by activating the innate immune pathway and immunological cell death pathway. Pathway analyses of gene expression profiles revealed a DNA activated gene list regulated in 16 immune pathways. This gene list provides biomarkers of response to DNA treatment.
Resumen de: US20260232839A1
The present disclosure is a lipid nanoparticle including a composition including a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, in which the polymer and the protein have opposite charges at a predetermined pH. The lipid nanoparticle preferably has a protein encapsulated therein. In addition, when the particle diameter of the lipid nanoparticles is measured, the peak top of the particle diameter distribution is preferably at 80 nm to 120 nm.
Resumen de: US20260232758A1
An exemplary embodiment of the present disclosure provides an intracellular delivery complex, comprising at least one biomacromolecule, each of the at least one biomacromolecules having a first ionic net charge, and at least one hydrophobic counterion, each of the at least one hydrophobic counterions having a second ionic net charge opposite the first ionic net charge, and wherein the complex is not encapsulated in a nanocarrier. Another embodiment provides a method of delivering a biomacromolecule into a cell, which comprises providing a biomacromolecule as described herein, a hydrophobic counterion as described herein, and mixing the two under conditions effective to form a complex capable of entering a cell. Another embodiment provides a method of administering a biomacromolecule into a cell, which comprises providing the intracellular delivery complex of the present disclosure, and administering the intracellular delivery complex to a subject, such that the complex enters a cell of the subject.
Resumen de: US20260232781A1
0000 Described herein is a composition for immunization of a mammal against an infection by a parasite. The composition includes an extracellular vesicle produced by a red blood cell infected with the parasite; and a pharmaceutically acceptable carrier for parenteral administration. Also described herein is a method for immunizing a subject against an infection by a parasite. The method includes administering to the subject an effective amount of an extracellular vesicle exuded by the parasite, which resides with the host red blood cell.
Resumen de: US20260232589A1
A nanopreparation loaded with trabectedin and paclitaxel is provided. The nanopreparation loaded with trabectedin and paclitaxel includes a non-targeted drug-loaded micelle loaded with paclitaxel and a first targeting group linked to a first micelle carrier, where the non-targeted drug-loaded micelle has a first shell-core structure, and the first micelle carrier is prepared from poly(ε-caprolactone)-poly(2-ethyl-2-oxazoline) (PCL-PEOz), where a hydrophobic block of PCL and paclitaxel jointly form a core of the first shell-core structure, and a hydrophilic block of PEOz forms a shell of the first shell-core structure; and the first targeting group is linked via an amide bond formed between —NH2 on a surface of the first targeting group and —COOH at a terminus of the PEOz on a surface of the shell.
Resumen de: WO2026166561A1
Disclosed in the present application are an ionizable cationic lipid and the use thereof. In the ionizable cationic lipid of the present application, adsorption with a biological drug such as a nucleic acid is formed by means of the structural design of the head group, thereby improving the encapsulation efficiency, a branched structure is formed at the tail group by using a saturated or unsaturated fatty chain, and the head group and the tail group are linked by using an ester bond, which facilitates in-vivo degradation to reduce toxicity. The design of the unsaturated fatty chain increases the membrane fluidity during endosomal release, and effectively improves the release efficiency of a biological drug. Moreover, the ionizable cationic lipid of the present application has a good temperature stability, which not only improves the product quality, but also expands the product accessibility. In summary, the ionizable cationic lipid of the present application has the advantages of a high encapsulation efficiency, a low toxicity, a high endosomal release efficiency, a good temperature stability, etc., and can improve the quality and therapeutic effect of a lipid nanoparticle drug, thus providing a new solution and choice for biological drug delivery.
Resumen de: AU2025265466A1
Disclosed herein is a flowable polymer solution for intravascular (arterial and venous) administration comprising the polymer and at least one solvent, the polymer comprising a first monomer for binding water; a second monomer for imparting mechanical properties; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting thermoresponsive phase-transition behaviour. In an embodiment, the solution further comprises at least one radiographic intravenous contrast agent is selected from contrast media for digital subtraction angiography (DSA), computer tomography (CT) and fluoroscopy such as iodinated contrast media, tantalum, and bismuth-based materials (e.g., bismuth chelate), heavy metal chelates contrast media for MRI including gadolinium agents (e.g., gadobutrol) or MRI nanoparticles.
Resumen de: US20260232788A1
0000 The present invention relates to a dengue virus messenger ribonucleic acid (mRNA) vaccine. In particular, the vaccine includes an mRNA encoding a mutant envelop (E) protein of dengue virus at position 8 and/or 101 formulated in lipid nanoparticles. The mRNA vaccine of the present invention is safe and effective, which causes enhanced production of neutralizing antibodies against multiple serotypes of dengue virus and reduced antibody dependent enhancement (ADE) response.
Resumen de: US20260233124A1
0000 The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.
Resumen de: US20260232847A1
0000 Therapeutic methods, imaging methods, and inorganic nanotherapeutic imaging agents and inorganic nanoimaging agents. Inorganic nanotherapeutic imaging agents and inorganic nanoimaging agents are used in therapeutic methods and imaging methods. The inorganic nanotherapeutic imaging agents and inorganic nanoimaging agents are, for example, silica or aluminosilicate nanoparticles functionalized with fluorescent group(s), targeting groups, and therapeutic groups. Therapeutic methods can be used to treat and imaging methods can be used to investigate or diagnose inflammatory joint diseases, such as, for example, rheumatoid arthritis, osteoarthritis, or both, in a subject.
Resumen de: US20260232592A1
0000 The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li<+> ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.
Resumen de: WO2022040641A2
Ionizable phospholipids and compositions and methods relating thereof are provided herein. In some aspects, the ionizable phospholipids provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
Resumen de: WO2025076127A1
Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is an LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Resumen de: WO2020056333A1
A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal.
Resumen de: WO2022212838A1
Disclosed herein are novel dendritic structures that can be used in combination with other lipid components to form nanoparticles with nucleic acids, to facilitate the intracellular delivery of nucleic acids both in vitro and in vivo. Nanoparticle compositions comprising the compounds and methods for their use for treating or preventing diseases or conditions are also provided.
Resumen de: AU2021393593A1
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
Resumen de: EP4789683A1
The present invention relates to a nanosystem for use in capturing, directing and/or transporting biologically active molecules to adipose tissue, therefore serving to treat illnesses such as obesity and/or type 2 diabetes.
Resumen de: US2025114306A1
0000 The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol %; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol % and 65 mol %; and an ionizable cationic amino lipid present at a content of between 15 mol % and 45 mol %; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol % content is relative to total lipid present in the lipid nanoparticle.
Resumen de: WO2025076082A1
The present disclosure describes peptide nanosponges comprising a plurality of self-assembled peptide building blocks. The plurality of self-assembled peptide building blocks comprises a first peptide building block comprising: a branched polymeric core comprising at least three arms; a first block co-peptide covalently linked to one of said arms, wherein said first block co-peptide comprises a first peptide block and a second peptide block which is different from the first peptide block; a lipid-based capping moiety covalently attached to the first block co-peptide; and a therapeutically active compound covalently attached via a cleavable linkage to the first block co-peptide. Advantageously, the block co-peptide is covalently attached to the core such that it is resistant to enzymatic cleavage from the core.
Resumen de: WO2025074292A2
The invention relates to lipid nanoparticles, immunogenic compositions and methods for use thereof.
Resumen de: WO2025076113A1
Ionizable cationic lipids, methods for synthesizing the same, intermediates useful in synthesis of the ionizable cationic lipids, and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for delivering nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.
Resumen de: WO2025073055A1
Provided is a method for inducing an immune response in a subject to treat or prevent a disease or disorder, the method comprising administering a vaccine comprising a lipid nanoparticle encapsulating nucleic acid encoding an antigenic protein, peptide or fragment thereof, a neutral lipid content of from 30 mol% to 70 mol%, a sterol or derivative thereof and an ionizable cationic amino lipid at between 5 and 50 mol%, and a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0 mol% to 5 mol%, wherein the administering of the lipid nanoparticle results in the immune response against the antigenic protein, peptide or fragment thereof expressed by the mRNA in the subject, wherein each mol% is measured relative to a total lipid content of the lipid nanoparticle. The disclosure further provides vaccine compositions and use of such compositions to induce an immune response in a subject.
Nº publicación: EP4788382A1 12/08/2026
Solicitante:
UNIV CASE WESTERN RESERVE [US]
CASE WESTERN RESERVE UNIVERSITY
Resumen de: AU2024356988A1
Gas-filled nanobubbles for negatively charged genetic material delivery each includes a lipid membrane defining a gas containing internal void, wherein the lipid membrane includes a plurality of cationic lipids for complexing the negatively charged genetic material, an edge-activator incorporated between lipids of the membrane that enhances the flexibility of the membrane, and a membrane stiffener incorporated on an outer surface of the membrane that enhances the membrane's resistance to tearing.
BOPI
Sede Electrónica
